Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.71

+0.93%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$343.75M
EPS-0.4700
P/E Ratio-5.76
Earnings Date08/04/2026

naut

Total Debt

Last Annual Value

30.02M

3-Year CAGR

%

5-Year CAGR

44%

10-Year CAGR

20%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Total Debt

NAUT · NASDAQ
CompanyTotal Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
30.02M
-4.6%-0.0%N/A 
10.83M
-4.5%-7.2%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
0.00
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
64.85M
4.1%4.8%N/A
25.00M
-6.1%-18.4%68.8%
78.00K
6.3%-25.9%N/A
3.82M
-5.0%-6.5%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
334.90M
53.2%41.9%9.9%
638.00K
-19.8%N/AN/A
112.06K
N/AN/AN/A
502.67K
-40.2%-4.8%N/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.705, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.705